What does CUSIP 88339KAA0 represent in this 13F holders report?

CUSIP 88339KAA0 is the security identifier for 88339KAA0 - THERAVANCE BIOPHARMA INC - NOTE 3.250%11/0 used to aggregate holder disclosures.

How many institutions held 88339KAA0 - THERAVANCE BIOPHARMA INC - NOTE 3.250%11/0 in Q3 2022?

No institutional holders were reported for 88339KAA0 - THERAVANCE BIOPHARMA INC - NOTE 3.250%11/0 in Q3 2022; review adjacent reporting periods for trend context.

THERAVANCE BIOPHARMA INC - NOTE 3.250%11/0

CUSIP: 88339KAA0

Q3 2022 13F Holders as of 30 Sep 2022

Type / Class: Debt / NOTE 3.250%11/0
Total 13F principal: $0
Principal change: -$194,748,463
Total reported market value: $0
Number of holders: 0
Value change: -$208,840,000
Number of sells: 14

Quarterly Holders Quick Answers

What is CUSIP 88339KAA0?
CUSIP 88339KAA0 identifies 88339KAA0 - THERAVANCE BIOPHARMA INC - NOTE 3.250%11/0 in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Related Filing Research

Latest 13F filings for newly reported positions.
Latest Schedule 13D/13G reports for ownership changes outside 13F cadence.
Latest 10-Q/10-K reports for financial context tied to this issuer.
Recent insider transactions for executive and insider activity.
SEC investors directory and top value investors for manager drilldown.
Back to full security ownership history.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Previous quarter: Q2 2022

Recent filing periods for CUSIP 88339KAA0:

Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021 Q4 2020

THERAVANCE BIOPHARMA INC - NOTE 3.250%11/0

Q3 2022 13F Holders as of 30 Sep 2022

Quarterly Holders Quick Answers

Related Filing Research

Explore More Reporting Periods

There are no holders of THERAVANCE BIOPHARMA INC - NOTE 3.250%11/0 as of Q3 2022.